PRME - Latest News

Prime Medicine, Inc. (PRME), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $558.1M. Beta to the broader market is 2.31.

The article list below shows the most recent PRME headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PRME Headlines

Prime Medicine: Soon In The Clinic

seekingalpha.com - Aug 15, 2026

Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies t

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

zacks.com - Aug 6, 2026

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

zacks.com - Jul 30, 2026

Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

globenewswire.com - Jul 23, 2026

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets

Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.

defenseworld.net - Jul 21, 2026

Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc.

How News Affects PRME Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PRME's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PRME news questions

What is the latest PRME news headline?

The most recent PRME headline (Aug 15, 2026) is "Prime Medicine: Soon In The Clinic". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PRME news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PRME news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PRME options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.